CCS
CBPO

Crosspoint Capital Strategies’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Crosspoint Capital Strategies’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-90
Closed -$10K – 952
2015
Q2 		$10K Buy
90
+18
+25% +$1.89K ﹤0.01% 536
2015
Q1 		$7K Buy
72
+3
+4% +$224 ﹤0.01% 415
2014
Q4 		$5K Buy
+69
New +$4.28K ﹤0.01% 621

Other funds holding CBPO

WP
Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crosspoint Capital Strategies's CBPO Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2015, closing a stake of 90 shares — an estimated $10K sold.

Crosspoint Capital Strategies first reported a position in CBPO in Q4 2014 and held it in 3 quarters. The position peaked at $10K in Q2 2015. 106 funds tracked by Wall St. Rank hold CBPO as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 90 China Biologic Products Holdings, Inc. shares in Q3 2015, an estimated $10K.
  • Crosspoint Capital Strategies first reported a position in China Biologic Products Holdings, Inc. in Q4 2014 and held it in 3 quarters.
  • Crosspoint Capital Strategies's China Biologic Products Holdings, Inc. position peaked at $10K in Q2 2015.
  • 106 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.